EXPERT will address three major challenges that have limited mRNA therapy from displaying its full potential:

  • The ability to achieve functional target tissue delivery of mRNA by nanomedicine design
  • The capacity to efficiently reach target cell cytoplasm, the site of mRNA activity
  • The capability to circumvent adverse immune responses towards mRNA nanomedicines

Project Objectives

  • Development of mRNA Nanomedicines
  • Production of mRNA nanomedicines in a quality-by-design (QbD) approach
  • Good Manufacturing Practice scale-up and clinical translation
  • First in-man clinical study with mRNA nanomedicines for immunotherapy
  • Investigation of mRNA nanomedicines for heart failure patients